ReviewHistology and histopathology2020
Dual immune functions of IL-33 in inflammatory bowel disease.
Review in Histology and histopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential.Nature reviews. Immunology · 2026Review
- Gegen Qinlian Decoction Mitigates DSS-Induced Acute Colitis and Reinstates Gut Barrier Function in Mice, Correlating with Suppressed IL-33/ST2 Signaling.Journal of inflammation research · 2026Article
- Mutant LRRK2 exacerbates immune response and neurodegeneration in a chronic model of experimental colitis.Acta neuropathologica · 2023Article
- Expression of IL-21 and IL-33 in Intestinal Mucosa of Inflammatory Bowel Disease: An Immunohistochemical Study.Diagnostics (Basel, Switzerland) · 2023Article
- A Chemically Induced Experimental Colitis Model with a Simple Combination of Acetic Acid and Trinitrobenzene Sulphonic Acid.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- The hypoxic tissue microenvironment as a driver of mucosal inflammatory resolution.Frontiers in immunology · 2023Review
- Interleukin-33 deficiency prevents biliary injuries and repairments caused by Clonorchis sinensis via restraining type 2 cytokines.Parasites & vectors · 2022Article
- Single-cell atlas of multilineage cardiac organoids derived from human induced pluripotent stem cells.Life medicine · 2022Article
- Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis.Frontiers in immunology · 2022Review
- Interleukin-33/ Suppression of Tumorigenicity 2 in Renal Fibrosis: Emerging Roles in Prognosis and Treatment.Frontiers in physiology · 2021Review
- A single nucleotide polymorphism in theInternational journal of ophthalmology · 2021Article
- Intestinal Regulatory T Cells.Advances in experimental medicine and biology · 2021Article
- Editorial: DAMPs Across the Tree of Life.Frontiers in immunology · 2021Article
- IL-33 deficiency protects mice from DSS-induced experimental colitis by suppressing ILC2 and Th17 cell responses.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Article
- The Functional Roles of IL-33/ST2 Axis in Ocular Diseases.Mediators of inflammation · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Interleukin-33 (IL-33) has emerged as a critical regulator in a variety of diseases, including inflammatory bowel disease (IBD). IL-33 can be produced by various tissues and cells, and typically induces Th2-type immune responses via binding to the receptor ST2. In addition, accumulated data have shown that IL-33 also plays a modulatory role in the function of regulatory T cells (Tregs), B cells, and innate immune cells such as macrophages and innate lymphoid cells (ILCs). IBD, including Crohn's disease and ulcerative colitis, are characterized by aberrant immunological responses leading to intestinal tissue injury and destruction. Although IL-33 expression is increased in IBD patients and correlates with the patients' disease activity index, mechanistic studies to date have demonstrated both pathogenic and protective roles in animal models of experimental colitis. In this review, we will summarize the roles and mechanisms of IL-33 in IBD, which is essential to understand the pathogenesis of IBD and determine potential therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.